clinical trial · NCT00912964
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Urinary Bladder, OveractiveMirabegronPlacebo
brief summary
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
started
Apr 28, 2009
primary completion
Apr 27, 2010
completion
Apr 27, 2010
last updated
Nov 21, 2024
official title
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol